Debate over personalization methods

Personalized health artificial intelligence is splitting into two camps: one built on wearable data and clinical validation, the other arguing today’s models are still too averaged to capture individual biology. (x.com) A biomarker is a measurable sign of health, like heart rhythm, glucose, or sleep patterns. Recent reviews say wearables can turn continuous sensor streams into “digital biomarkers,” but only if those signals are verified, validated, and tied to meaningful clinical measures. (nature.com) That is the lane described by @thoughtson_tech, who said wearable signals can be processed and refined with artificial intelligence until they become clinically relevant markers rather than raw consumer-device data. The idea matches a broader push in digital medicine to move from step counts and heart-rate logs to signals a clinician can actually use. (x.com) (bmj.com) The counterargument came from @QuanMed_Ai, which said much of medical artificial intelligence is still trained on population averages and pushed “quantum biology” as a route to molecular-level personalization. Reviews of medical artificial intelligence bias say models can amplify errors and disparities when training data do not represent the patients they are used on. (x.com) (nature.com) Quantum biology studies whether quantum-scale effects, such as tunneling or coherence, help explain some biological processes. Separate reviews on quantum computing in medicine say the field is being explored for biomarker discovery, molecular simulation, and multi-omic analysis, but practical clinical use remains limited by hardware and regulatory constraints. (pmc.ncbi.nlm.nih.gov) (nature.com) The reimbursement fight sits underneath both arguments. Medicare’s remote patient monitoring program already covers some technology-enabled care, and the Centers for Medicare & Medicaid Services says clinicians can bill for covered remote monitoring services under existing rules. (cms.gov) Federal policy is also shifting toward payment tied to outcomes, not just device use. In a December 8, 2025 notice, the Food and Drug Administration said its TEMPO pilot would work with the Centers for Medicare & Medicaid Innovation ACCESS model, which uses recurring payments linked to measurable health outcomes for qualifying chronic conditions. (federalregister.gov) That puts pressure on health artificial intelligence companies to prove two things at once: that their personalization method reflects an individual patient, and that it changes outcomes a payer will recognize. The current argument is less about whether personalization sells and more about which evidence standard will get paid. (federalregister.gov) (cms.gov)